Abstract
RNA-binding proteins (RBPs) are proteins that physically and functionally bind to RNA to regulate the RNA metabolism such as alternative splicing, polyadenylation, transport, maintenance of stability, localization, and translation. There is accumulating evidence that dysregulated RBPs play an essential role in the pathogenesis of malignant tumors including a variety of types of sarcomas. On the other hand, prognosis of patients with sarcoma, especially with sarcoma in advanced stages, is very poor, and almost no effective standard treatment has been established for most of types of sarcomas so far, highlighting the urgent need for identifying novel therapeutic targets based on the deep understanding of pathogenesis. Therefore, defining the network of interactions between RBPs and disease-related RNA targets will contribute to a better understanding of sarcomagenesis and identification of a novel therapeutic target for sarcomas.
Funding Information
  • Japan Agency for Medical Research and Development (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • Japan Agency for Medical Research and Development (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • Japan Society for the Promotion of Science (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • Japan Society for the Promotion of Science (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • Japan Science and Technology Agency (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • the National Cancer Center Research and Development Funds (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • the ASH Global Research Award from the American Society of Hematology (ASH) (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • the CDP Special Fellow Achievement Award from Leukemia and Lymphoma Society (LLS) (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • the Shimadzu Science Foundation (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • The YASUDA Medical Foundation (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • The Chemo-Sero-Therapeutic Research Institute (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • The Sumitomo Foundation (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • The Uehara Memorial Foundation (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • the Princess Takamatsu Cancer Research Fund (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • the Takeda Science Foundation (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • The Mochida Memorial Foundation for Medical and Pharmaceutical Research (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • The Astellas Foundation for Research on Metabolic Disorders (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)
  • the IMSUT Joint Grant (JP22am0401007, JP22jm0210085, 21H04828, 19K24691, 22-221036124, 2020-A-2, New-2022-K2005)

This publication has 89 references indexed in Scilit: